Abstract: The invention provides new uses, compositions and methods of administration for specific binding agents to von Wiliebrand Factor (vWF) in patients with thromboembolic disorders and in particular new combined uses with thrombolytic agents such as tissue plasminogen activator in patients with thromboembolic disorders such as e.g. ischemic stroke. Furthermore, a new group of vWF binding agents and an improved Middle Cerebral Artery Thrombosis Model in guinea pigs to study the effects of stroke such as ischemia (oxygen and glucose depriviation) and hemorrhage (bleeding), in particular hemorrhage, are provided.

Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond.

Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.

Abstract: The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.

Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.

Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.

Abstract: The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.

Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.

Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomelic counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.

Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.

Abstract: The present invention describes a method for diagnosing tumors of the reproductive organs which is characterized by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumor is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumor of the reproductive organs.

Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Abstract: The invention relates to novel methods for controlling the glycosylation of a protein and the protein produced thereby. An exemplary method of the invention comprises producing a protein comprising a decreased level of glycosylation, e.g., the protein comprises fewer glycans or fewer saccharides at the glycosylation site, by culturing a host cell expressing the protein in the presence of a glycosylation inhibitor. In an exemplary method of the invention, the biological characteristics of the protein are altered by the decreased level of glycosylation, e.g., the binding of the protein with its target ligand is modified.

Abstract: Several aspects of this invention relate to diagnosis of diabetic states in a mammal using protein isoforms. In some aspects, it relates to a method for determining the diabetic state of a mammal. This method can include, for example, (a) measuring the serum concentration of one or more protein isoforms, (b) analyzing the serum concentration of the one or more protein isoforms, and (c) determining the diabetic state of the mammal. Other aspects include kits used to perform the method. Further aspects are the isolated protein isoforms themselves, and their methods of isolation.

Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Abstract: The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.

Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.

Abstract: Provided are pharmaceutical compositions, preparations or formulations including a compounds or constructs that include at least one amino acid sequence that is directed against serum albumin and at least one therapeutic moiety. The pharmaceutical compositions, preparations or formulations are preparations or formulations that are suitable for and/or intended for, e.g., pulmonary administration. Methods for use of the pharmaceutical compositions, preparations or formulations also are provided.

Abstract: Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of hepatocyte growth factor activator function, and the identification and uses of said modulators.

Abstract: The invention provides polypeptide, nucleic acid and other compositions. Polypeptide, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder, or reducing levels of LDL or oxLDL.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.

Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.

Abstract: The invention provides methods of identifying proteins and polypeptides and their cognate polynucleotides that are expressed by cells under one environmental condition and not under a second environmental condition. The invention also provides compositions for the treatment and detection of cancer, including colorectal cancer.

Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.

Abstract: Methods for characterizing a test subject's, particularly a human test subject's, risk of having cardiovascular disease or developing cardiovascular disease are provided. Also provided are methods for characterizing a test subject's risk of experiencing a complication of cardiovascular disease near term. The methods comprise determining levels of one or more carbamylated biomarkers in a bodily fluid of the test subject and/or comparing these levels with a reference value. In certain embodiments, the carbamylated biomarkers are carbamylated albumin, carbamylated fibrinogen, carbamylated immunoglobulin and carbamylated apolipoprotein A. In other embodiments, particularly where the test subject does not have clinical evidence of renal disease, the carbamylated biomarker is free and/or total peptide-bound homocitrulline.

Abstract: Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.

Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.

Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.

Abstract: The present invention relates to proteomic markers for early detection of hepatocellular carcinoma, compositions for detecting changes of these proteomic markers, kits for detection of hepatocellular carcinoma, methods for detecting proteomic markers including these compositions, methods for screening drugs for hepatocellular carcinoma using these proteomic markers, and antibodies specific for these proteomic markers.

Abstract: This application includes description of antibodies for specifically detecting prions of human origin and methods for detecting pathogenic prions. In some embodiments, the antibodies bind to an epitope characteristic of a human prion protein which is not found in the prion proteins of other species. In some embodiments, the antibodies are not cross-reactive with cow, Syrian Gold hamster, mouse, or rat prions. The application also includes a conformation-dependent immunoassay method for detecting pathogenic prions in a sample containing a prion (PrP) protein. The PrP protein may be present in a first conformation and a second conformation, such as PrPc and PrPSc in which the two conformations have different binding affinity for the antibody used to detect them.

Abstract: The present invention relates to a method of diagnosing hereditary angioedema type III (HAE III) or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a hereditary angioedema type III or in a subject being suspected of being a carrier for hereditary angioedema type III, the method comprising determining in vitro from a biological sample of said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a hereditary angioedema type III or a predisposition thereto.

Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.

Abstract: There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps: measuring the amount of apoA-IV in a body liquid or tissue sample of a human, and comparing the measured amount of apoA-IV with a reference value.

Abstract: Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation.

Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.

Abstract: The present invention provides integrin ?IIb?3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting platelet aggregation using the antibodies and peptides are also provided.

Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.

Abstract: A bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), where free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Also disclosed is a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.

Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.

Abstract: This invention relates to selective activation of the alternative pathway (AP) using anti-Properdin antibodies. Specifically, the invention relates to methods for treating an AP complement-mediated pathology or AP mediated condition in a subject by contacting the subject with an anti-Properdin antibodies. Likewise, properdin knockout transgenic non-human mammals and their use are provided.